Form 4: Elanco Animal Health CEO Jeffrey Simmons Reports Acquisition of Deferred Stock Units

Elanco Animal Health's CEO, Jeffrey Simmons, reports the acquisition of deferred stock units convertible to common stock.

Summary

• On May 16, 2025, Jeffrey N. Simmons, CEO and Director of Elanco Animal Health Inc., acquired 214.3375 deferred stock units.
• These units are convertible to common stock or cash equivalent upon termination of employment or during a specified future year.
• The price of the deferred stock units was $12.92.
• Following the transaction, Simmons directly owns 16,249.094 shares of Elanco Animal Health Inc.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. It reflects standard executive compensation practices and insider confidence, without indicating any specific positive or negative events.

Positives

• The acquisition of deferred stock units by the CEO demonstrates confidence in the company's future performance.

Future Outlook

The deferred stock units will settle in cash or shares of Company common stock following termination of employment or during a specified future year in accordance with Executive Deferral and Stock Match Plan.

Industry Context

This filing is a routine disclosure related to executive compensation and stock ownership, common in publicly traded companies. It provides transparency regarding the alignment of management's interests with those of shareholders.

Stakeholder Impact

• The acquisition of deferred stock units by the CEO signals confidence in the company's future, which can positively influence shareholder sentiment.

Key Dates

Keywords

Elanco Animal Health, Jeffrey Simmons, deferred stock units, Form 4, beneficial ownership, common stock, CEO, ELAN